Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05689099 | A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose | PHASE1 | COMPLETED | 20 | — | — | Jan 17, 2023 | May 30, 2023 | Oct 15, 2024 | 1 | United States |
Measured in hours\*nanomoles per liter (h\*nmol/L).
Measured in nanomoles per liter (nmol/L).
| Arm | Type | Description |
|---|---|---|
| Sequence A | EXPERIMENTAL | Participants will be administered a single subcutaneous (s.c.) dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 2. |
| Sequence B | EXPERIMENTAL | Participants will be administered a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 2. |
| Name | Type | Description |
|---|---|---|
| Semaglutide B, 1.34 mg/mL | DRUG | Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously. |
| Semaglutide B, 0.68 mg/mL | DRUG | Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously. |
Inclusion Criteria: * Male or female * Aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 20.0 and 29.9 kilograms per meter square (kg/m\^2) (both inclusive) Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pr...